Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence

BACKGROUND: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) has limited progression‐free survival (PFS) benefit. We hypothesized that adding cetuximab to methotrexate improves PFS. METHODS: In the phase‐Ib‐study, patients with R/M SCCHN received met...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Head Neck
Main Authors: Ham, Janneke C., van Meerten, Esther, Fiets, W. Edward, Beerepoot, Laurens V., Jeurissen, Frank J. F., Slingerland, Marije, Jonker, Marianne A., Husson, Olga, van der Graaf, Winette T. A., van Herpen, Carla M. L.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7216894/
https://ncbi.nlm.nih.gov/pubmed/31903657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.26053
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados